Frequencies of human leukocyte antigen alleles and haplotypes among Japanese patients with age-related macular degeneration
Stem cell therapy is a potential treatment for retinal disorders. We are currently exploring treating HLA matched patients of age-related macular degeneration (AMD) by using allogenic retinal pigment epithelium cells derived from induced pluripotent stem cells (iPS-RPE) from human leukocyte antigen (HLA) homozygote donors. The purpose of this study was to investigate the frequency of HLA class I and II alleles and haplotypes in Japanese patients with AMD.
Cross-sectional observation clinical study.
A total of 138 consecutive patients diagnosed with neovascular AMD (mean age, 76.0 ± 7.8 years, 105 men) and 300 controls were included in the study. The frequencies of HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 alleles were determined using illumina MiSeq platform. Frequencies of HLA alleles at six loci in patients with AMD were compared with those of the controls.
The alleles with the highest prevalence at each locus were A*24:02 (29.7%), B*52:01 (15.5%), C*12:02 (16.1%), DRB1*09:01 (19.1%), DQB1*06:01 (23.2%), and DPB1* 05:01 (40.5%). There were no significant associations between the HLA alleles and AMD. The most common haplotype was A*24:02-B*52:01-C*12:02-DRB1*15:02-DQB1*06:01-DPB1*09:01, with a 9.8% genetic frequency among all haplotypes, detected in 18.8% of the patients.
The genotype of HLA in patients with AMD was not different from that in the Japanese control population. Thus, therapy with iPS-RPEof the most frequent HLA haplotype could be a feasible alternative for AMD in a wider population.
KeywordsAge-related macular degeneration Haplotype frequency Human leukocyte antigen Japan Induced pluripotent stem cells
This work was supported by the HLA Foundation laboratory. Although this study did not receive specific funding, we received normal data from the HLA Foundation laboratory. We thank them for their help in providing the data. We thank Dr Noriko Miyamoto and Dr Akihiro Nishida for their help in acquisition of informed consent. We also thank for professor. Goji Tomita for helpful advice. This paper received editorial support from Editage.
Conflicts of interest
S. Takagi, Grant (Alcon, AMO, HOYA, Senju), Lecture fee (Alcon); M. Mandai, Grant (Sumitomo Dainippon Pharma, Tomey), Consultant fees (Alcon, Bayer, Healios, Otsuka, Santen, Senju); Y. Hirami, Grant (Alcon, AMO, HOYA, Senju), Lecture fees (Alcon, Bayer, Santen); S. Sugita, None; M. Takahashi, Grant (Healios, Hitachi, Nichirei Biosciences, Nitta Biolab, Sagawa, Sanplatec, Santen, Shibuya, Sumitomo Dainippon Pharma, Tomey), Consultant fees (Alcon, Astellas, DAI-DAN, Eisai, Healios, Novaris, Sysmex, Takeda, Topcon, Toray); Y. Kurimoto, Grant (Alcon, HOYA, Santen, Senju), Consultant fees (Alcon, AMO, Bayer, Cannon, Kowa, Otsuka, Pfizer, Santen, Senju).
- 2.Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: 2-year results of the ANCHOR study. Ophthalmology. 2009;116(57–65):e5.Google Scholar
- 6.van Zeeburg EJ, Maaijwee KJ, Missotten TO, Heimann H, van Meurs JC. A free retinal pigment epithelium-choroid graft in patients with exudative age-related macular degeneration: results up to 7 years. Am J Ophthalmol. 2012;153(120–7):e2.Google Scholar
- 15.Craig J, Wekerle T, Segev D, LEchler R, Oberbauer R. The tragedies for long term preservation of kidney graft function. Lancet. 2017;3(5):e15216.Google Scholar
- 23.Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch’s membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 2001;20:705–32.CrossRefPubMedGoogle Scholar
- 28.Cao K, Hollenbach J, Shi X, Shi W, Chopek M, Fernandez-Vina MA. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol. 2001;62:1009–30.CrossRefPubMedGoogle Scholar